Drinabant is a selective CB1 receptor antagonist under investigation varyingly as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Drinabant may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. Coadministration of olanzapine and drinabant attenuated body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility. Sanofi has outlicensed global development and commercialization rights to drinabant to Opiant Pharmaceuticals, which said it plans to start developing the acute cannabinoid overdose (ACO) candidate in the 2019 year. Opiant said drinabant will be developed as an injectable for administration in an emergency department setting.